Research programme: anti-inflammatory therapeutics - Omeros Corporation

Drug Profile

Research programme: anti-inflammatory therapeutics - Omeros Corporation

Alternative Names: anti MASP-3 antibody - Omeros Corporation; anti-MASP-2 monoclonal antibody - Omeros Corporation; MASP-2 therapeutics - Omeros Corporation; MASP-3 therapeutics - Omeros Corporation; OMS 906

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Omeros Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Mannose binding protein associated serine protease inhibitors; MASP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Haemolytic uraemic syndrome; Inflammation; Myocardial reperfusion injury; Paroxysmal nocturnal haemoglobinuria; Reperfusion injury; Stroke

Most Recent Events

  • 10 Nov 2016 Pharmacodynamics data from a preclinical trial released by Omeros Corporation
  • 10 Aug 2016 Pharmacodynamics data from a preclinical trial in Paroxysmal nocturnal haemoglobinuria released by Omeros
  • 05 Aug 2016 Pharmacodynamics data from a preclinical trial in Inflammation released by Omeros
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top